Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Designing Portfolios With Purpose: Fixed-Income Investments

    Optimize portfolio diversification by incorporating longer-term fixed-income investments with William Blair’s capabilities.

    Read more

  • Retail Resilience Amidst Uncertainty

    Consumer behavior often helps gauge the overall health of the economy. William Blair’s Phillip Blee breaks down the potential impact of trade tensions and how retailers may prepare for further developments.

    Read more

  • The Trade-Offs of Tariffs: Compelling Growth Opportunities

    In a recent episode of William Blair Investment Management’s podcast, The Active Share, experts discuss tariff implications and compelling growth opportunities in Europe and China.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures